# Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

> **NCT06447779** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MAXVAX Biotechnology Limited Liability Company** · enrollment: 25000 (estimated)

## Conditions studied

- Herpes Zoster

## Interventions

- **BIOLOGICAL:** Recombinant Zoster Vaccine (CHO Cell)
- **BIOLOGICAL:** NaCl solution Placebo

## Key facts

- **NCT ID:** NCT06447779
- **Lead sponsor:** MAXVAX Biotechnology Limited Liability Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-07-13
- **Primary completion:** 2025-09
- **Final completion:** 2027-09
- **Target enrollment:** 25000 (ESTIMATED)
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06447779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06447779, "Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06447779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*